Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis
Jerzy P. Szaflarski, Hervé Besson, Vicente Villanueva
Objective To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. Methods EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice.
Outcomes included 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor?related epilepsy [BTRE], and traumatic brain injury-related epilepsy [TBIE]).
Results At 12 months,+/=50% seizure reduction was achieved in 35.6% (n=264), 38.7% (n=310), 41.7% (n=24), 34.1% (n=41), and 50.0% (n=28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n=318), 13.7% (n=424), 29.4% (n=34), 11.4% (n=44), and 13.8% (n=29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n=403), 30.7% (n=605), 33.3% (n=51), 39.7% (n=68), and 27.1% (n=49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n=283), 10.0% (n=410), 16.7% (n=36), 12.5% (n=48), and 3.0% (n=33), respectively.
Conclusions BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.